Table 3 Characteristics of the eligible study.
Title | Author, year | Country | Study design | Total cases | Treatment | pCR definition | BMI category and comparison |
|---|---|---|---|---|---|---|---|
Predictive factors of pathologic complete response in HER2- positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab | Ding et al.15 | China | Retrospective study | 88 | NAC+Trastuzumab | ypT0/is, ypN0 | >25 vs ≤25 |
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer | A-S. Hamy16 | France | Retrospective study | 144 | NAC+Trastuzumab | ypT0/is, ypN0 | <19 vs 19-25; >25 vs 19-25 |
Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy | Tong et al.14 | China | Retrospective study | 81 | NAC+Trastuzumab | ypT0/is, ypN0 | ≥ 25 vs <25 |
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial | Di Cosimo et al.11 | Italy | Prospective study | 454 | NAC+Trastuzumab; NAC+lapatinib; NAC+Trastuzumab+lapatinib | ypT0/is | <18.5 vs 18.5 ≤ BMI < 25; ≥ 25 vs 18.5 ≤ BMI < 25; ≥ 30 vs 18.5 ≤ BMI < 25 |
Carboplatin dose capping affects pCR rate in HER2‐positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP) | Howell et al.13 | UK | Retrospective study | 124 | NAC+Trastuzumab+Pertuzumab | ypT0/is, ypN0 | ≥ 25 vs <25 |
Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy | Takada et al.17 | Japan | Retrospective study | 93 | NAC+Trastuzumab | ypT0/is, ypN0 | >18.5 vs ≤18.5; >25 vs ≤25; >30 vs ≤30 |
